

3rd Quarter 2021 Results

3rd Quarter 2021 Sales

Worldwide Increased \uparrow **\$23.3B** **10.7%** | Excluding acquisitions/divestitures on an operational basis **10.6%*** Worldwide Increased \uparrow

Diluted Earnings Per Share

Increased \uparrow **\$1.37** | **3.0%**

Adjusted Diluted Earnings Per Share*

Increased \uparrow **\$2.60** | **18.2%**



Alex Gorsky
Chairman and Chief Executive Officer
Johnson & Johnson

“Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health. In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of our stakeholders, while also successfully investing in a pipeline of innovation and key commercial platforms to drive our future growth. I am incredibly proud of our Company’s transformative growth over the last decade. As I prepare to transition the role of CEO to Joaquin Duato in January, I want to extend my deepest gratitude to our colleagues around the globe who work tirelessly to deliver solutions to address the world’s most urgent and unmet healthcare challenges.”

\$3.7 Billion

Worldwide Consumer Health Sales

Consumer Health worldwide reported sales increased 5.3% or 4.1% operationally¹. Primary operational drivers:



Aveeno

TYLENOL

Motrin^{IB}

ZARBEE'S
NATURALS


Imodium

Aveeno
baby

\$13.0 Billion

Worldwide Pharmaceutical Sales

Pharmaceutical worldwide reported sales increased 13.8% or 13.2% operationally¹. Primary operational drivers:



Stelara
(ustekinumab)

DARZALEX
(daratumumab)
injection for intravenous infusion
100 mg/5 mL, 400 mg/20 mL

Tremfya
(guselkumab)

Erleada
(apalutamide) 60 mg tablets

Uptravi
selexipag
tablets | 200-600 mg

INVEGA SUSTENNA
paliperidone palmitate
extended-release
orally disintegrating tablets

Opsumit
macitentan

\$6.6 Billion

Worldwide Medical Devices Sales

Medical Devices worldwide reported sales increased 8.0% or 7.0% operationally¹. Primary operational drivers:



Electrophysiology



Wound Closure



Surgical Vision



Contact Lens



Energy



Biosurgery



Endocutters

Note: values may have been rounded

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson’s earnings release issued on October 19, 2021, available at <http://www.investor.jnj.com/sales-earnings.cfm>.

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

¹Non-GAAP measure; excludes the impact of translational currency.

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements” included in the Johnson & Johnson earnings release issued on October 19, 2021, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.